Publications by authors named "Angimar Uriepero-Palma"
Article Synopsis
- Preclinical studies have shown that in vitro-differentiated Th17 cells can be effective in solid tumors, but their potential in enhancing adoptive cell therapy (ACT) for hematological cancers like chronic lymphocytic leukemia (CLL) is not yet explored.
- CLL, a type of B-cell cancer, faces issues with resistance to targeted therapies, and existing T-cell treatments like CAR T cells have seen limited success due to T-cell dysfunction and immunosuppressive responses.
- This research highlights the successful polarization of CD4 T cells into a Th17 phenotype from a CLL mouse model, demonstrating improved memory properties and persistence in treating leukemia, marking a significant step towards enhancing ACT efficacy in CLL with Th17 CAR T
Article Synopsis
- Advancements in CLL/SLL treatments have led to a study exploring a new frontline therapy combining high-dose methylprednisolone, ofatumumab, and lenalidomide for treatment-naive patients.
- In a phase 2 study involving 45 patients, the treatment showed a 96% overall response rate and a median progression-free survival of 54.4 months, with 29% achieving a complete response.
- Although the treatment was generally well tolerated, with manageable side effects, the effectiveness compared to existing treatments remains uncertain, highlighting the need for further research in the frontline setting.